Literature DB >> 21245138

Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation.

Marina Khrapunovich-Baine1, Vilas Menon, Chia-Ping Huang Yang, Peter T Northcote, John H Miller, Ruth Hogue Angeletti, Andras Fiser, Susan Band Horwitz, Hui Xiao.   

Abstract

Microtubule stabilizing agents (MSAs) comprise a class of drugs that bind to microtubule (MT) polymers and stabilize them against disassembly. Several of these agents are currently in clinical use as anticancer drugs, whereas others are in various stages of development. Nonetheless, there is insufficient knowledge about the molecular modes of their action. Recent studies from our laboratory utilizing hydrogen-deuterium exchange in combination with mass spectrometry (MS) provide new information on the conformational effects of Taxol and discodermolide on microtubules isolated from chicken erythrocytes (CET). We report here a comprehensive analysis of the effects of epothilone B, ixabepilone (IXEMPRA(TM)), laulimalide, and peloruside A on CET conformation. The results of our comparative hydrogen-deuterium exchange MS studies indicate that all MSAs have significant conformational effects on the C-terminal H12 helix of α-tubulin, which is a likely molecular mechanism for the previously observed modulations of MT interactions with microtubule-associated and motor proteins. More importantly, the major mode of MT stabilization by MSAs is the tightening of the longitudinal interactions between two adjacent αβ-tubulin heterodimers at the interdimer interface. In contrast to previous observations reported with bovine brain tubulin, the lateral interactions between the adjacent protofilaments in CET are particularly strongly stabilized by peloruside A and laulimalide, drugs that bind outside the taxane site. This not only highlights the significance of tubulin isotype composition in modulating drug effects on MT conformation and stability but also provides a potential explanation for the synergy observed when combinations of taxane and alternative site binding drugs are used.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245138      PMCID: PMC3064228          DOI: 10.1074/jbc.M110.162214

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes.

Authors:  W B Derry; L Wilson; I A Khan; R F Luduena; M A Jordan
Journal:  Biochemistry       Date:  1997-03-25       Impact factor: 3.162

2.  Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.

Authors:  P Giannakakou; D L Sackett; Y K Kang; Z Zhan; J T Buters; T Fojo; M S Poruchynsky
Journal:  J Biol Chem       Date:  1997-07-04       Impact factor: 5.157

Review 3.  The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents.

Authors:  E K Rowinsky
Journal:  Annu Rev Med       Date:  1997       Impact factor: 13.739

4.  Structure of the alpha beta tubulin dimer by electron crystallography.

Authors:  E Nogales; S G Wolf; K H Downing
Journal:  Nature       Date:  1998-01-08       Impact factor: 49.962

5.  In vitro analysis of microtubule assembly of isotypically pure tubulin dimers. Intrinsic differences in the assembly properties of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers in the absence of microtubule-associated proteins.

Authors:  Q Lu; R F Luduena
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

6.  Microtubule dynamics in vitro are regulated by the tubulin isotype composition.

Authors:  D Panda; H P Miller; A Banerjee; R F Ludueña; L Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

7.  Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

Authors:  R J Kowalski; P Giannakakou; E Hamel
Journal:  J Biol Chem       Date:  1997-01-24       Impact factor: 5.157

8.  Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.

Authors:  D M Bollag; P A McQueney; J Zhu; O Hensens; L Koupal; J Liesch; M Goetz; E Lazarides; C M Woods
Journal:  Cancer Res       Date:  1995-06-01       Impact factor: 12.701

9.  Role of GTP hydrolysis in microtubule dynamics: information from a slowly hydrolyzable analogue, GMPCPP.

Authors:  A A Hyman; S Salser; D N Drechsel; N Unwin; T J Mitchison
Journal:  Mol Biol Cell       Date:  1992-10       Impact factor: 4.138

10.  Removal of beta III isotype enhances taxol induced microtubule assembly.

Authors:  Q Lu; R F Luduena
Journal:  Cell Struct Funct       Date:  1993-06       Impact factor: 2.212

View more
  29 in total

1.  Zampanolide, a potent new microtubule-stabilizing agent, covalently reacts with the taxane luminal site in tubulin α,β-heterodimers and microtubules.

Authors:  Jessica J Field; Benet Pera; Enrique Calvo; Angeles Canales; Didier Zurwerra; Chiara Trigili; Javier Rodríguez-Salarichs; Ruth Matesanz; Arun Kanakkanthara; St John Wakefield; A Jonathan Singh; Jesús Jiménez-Barbero; Peter Northcote; John H Miller; Juan Antonio López; Ernest Hamel; Isabel Barasoain; Karl-Heinz Altmann; José Fernando Díaz
Journal:  Chem Biol       Date:  2012-06-22

2.  Structural evidence for cooperative microtubule stabilization by Taxol and the endogenous dynamics regulator MAP4.

Authors:  Hui Xiao; Hui Wang; Xuechun Zhang; Zongcai Tu; Chloë Bulinski; Marina Khrapunovich-Baine; Ruth Hogue Angeletti; Susan Band Horwitz
Journal:  ACS Chem Biol       Date:  2012-02-06       Impact factor: 5.100

3.  Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy.

Authors:  Nichole E LaPointe; Gerardo Morfini; Scott T Brady; Stuart C Feinstein; Leslie Wilson; Mary Ann Jordan
Journal:  Neurotoxicology       Date:  2013-05-24       Impact factor: 4.294

Review 4.  Peloruside, laulimalide, and noscapine interactions with beta-tubulin.

Authors:  Melissa M Gajewski; Laleh Alisaraie; Jack A Tuszynski
Journal:  Pharm Res       Date:  2012-06-26       Impact factor: 4.200

5.  Physical and functional interaction sites in cytoplasmic domains of KCNQ1 and KCNE1 channel subunits.

Authors:  Jerri Chen; Zhenning Liu; John Creagh; Renjian Zheng; Thomas V McDonald
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-12-13       Impact factor: 4.733

6.  Structural elements of an NRPS cyclization domain and its intermodule docking domain.

Authors:  Daniel P Dowling; Yan Kung; Anna K Croft; Koli Taghizadeh; Wendy L Kelly; Christopher T Walsh; Catherine L Drennan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

7.  Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding.

Authors:  Adrian Begaye; Shana Trostel; Zhiming Zhao; Richard E Taylor; David C Schriemer; Dan L Sackett
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

8.  Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity.

Authors:  A L Risinger; J Li; M J Bennett; C C Rohena; J Peng; D C Schriemer; S L Mooberry
Journal:  Cancer Res       Date:  2013-09-18       Impact factor: 12.701

9.  A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas.

Authors:  Jane E Churpek; Barbara Pro; Koen van Besien; Justin Kline; Kathy Conner; James L Wade; Fredrick Hagemeister; Theodore Karrison; Sonali M Smith
Journal:  Cancer       Date:  2013-01-10       Impact factor: 6.860

10.  2-(m-Azidobenzoyl)taxol binds differentially to distinct β-tubulin isotypes.

Authors:  Chia-Ping Huang Yang; Eng-Hui Yap; Hui Xiao; Andras Fiser; Susan Band Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.